L.a.n.c.e. Chemosensitivitätstestung auf höchstem Niveau · Laborgesellschaft für angewandte Neoplasieforschung und Cytostatika-Evaluation mbH ·

Literatur Zum ATP-TCA liegen zahlreiche wissenschaftliche Studienergebnisse vor. Vor allem die klinischen Studien belegen die hohe prädiktive Aussagefähigkeit des Verfahrens, das sich nicht nur bei der individuellen Therapieplanung, sondern auch in der Entwicklung innovativer Therapieregime bereits hervorragend bewährt hat.

Internationale Literatur
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Feasibility of chemosensitivity testing in soft tissue sarcomas.
Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Chemosensitivity testing in malignant melanoma.
Chemosensitivity testing in gynecologic oncology–dream or reality?

Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat MM, Untch M, Konecny G, Bruckner HW, Cree IA
Recent Results Cancer Res. 2003;161:221-30.

Division of Clinical and Experimental Gynecologic Oncology, Department of Gynecology and Obstetrics, University of Cologne Medical Center, Kerpener Strasse 34, 50931 Koln, Germany. kurbacher@web.de

After disappointing results achieved with older chemosensitivity tests such as the human tumor clonogenic assay (HTCA) during the 1980s, the last decade has seen a renaissance of the concept of individualized chemotherapy in oncology, markedly stimulated by the development of newer nonclonogenic assays. These methods appear to be able to overcome major technical limitations associated with older assays, now allowing for successful testing of most of the tumor specimens submitted. Currently, the ATP-based tumor chemosensitivity assay (ATP-TCA) can be regarded as the most sophisticated assay to investigate both solid samples and effusions derived from patients with various organ tumors. During the last 5 years, the ATP-TCA has been used successfully to screen for novel drug combinations for further clinical use in both ovarian and breast cancer such as mitoxantrone plus paclitaxel (NT) and treosulfan plus gemcitabine (TG), respectively. Clinical trials that have been set up in heavily pretreated patients with recurrent ovarian or breast cancer have convincingly confirmed the high activity of these combinations previously demonstrated in preclinical investigations using the ATP-TCA. In a recent phase II trial performed in 59 patients with relapsed ovarian carcinoma, ATP-TCA-directed therapy was able to triple the response rate and to double the survival time, compared with published empirical chemotherapy regimes. Preliminary results with ATP-TCA-directed therapy in breast cancer also evidenced promising response rates. These results have been confirmed by additional prospective clinical trials using other types of modern nonclonogenic assays. A phase III trial that is now actively recruiting patients with platinum-refractory ovarian cancer to verify the promising phase II studies will prove the further value of the ATP-TCA as a predictor applicable in routine clinical oncology.
Publication Types:
* Review
* Review, Tutorial